Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 2
1967 1
1968 1
1972 1
1975 1
1976 1
1977 4
1978 3
1979 2
1980 4
1981 3
1982 2
1983 3
1984 9
1985 11
1986 11
1987 10
1988 19
1989 17
1990 21
1991 20
1992 16
1993 23
1994 25
1995 25
1996 19
1997 31
1998 47
1999 43
2000 44
2001 69
2002 65
2003 55
2004 62
2005 85
2006 88
2007 84
2008 75
2009 67
2010 59
2011 65
2012 64
2013 66
2014 64
2015 68
2016 59
2017 57
2018 54
2019 52
2020 55
2021 62
2022 58
2023 62
2024 52
2025 56
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,839 results

Results by year

Filters applied: . Clear all
Page 1
Oxybutinyn.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000728 Free Books & Documents. Review.
No information is available on the use of oxybutynin during breastfeeding. Long-term use of oxybutynin might reduce milk production or milk letdown, but a single dose is not likely to interfere with breastfeeding. ...
No information is available on the use of oxybutynin during breastfeeding. Long-term use of oxybutynin might reduce milk produ …
Extended-release oxybutynin.
Comer AM, Goa KL. Comer AM, et al. Drugs Aging. 2000 Feb;16(2):149-55; discussion 156-7. doi: 10.2165/00002512-200016020-00008. Drugs Aging. 2000. PMID: 10755330 Review.
Extended-release oxybutynin (Ditropan XL) uses an osmotic system (OROS) to deliver a controlled amount of oxybutynin chloride into the gastrointestinal tract over a 24-hour period when taken once daily. ...Mean peak plasma concentrations are lower with extended-rele …
Extended-release oxybutynin (Ditropan XL) uses an osmotic system (OROS) to deliver a controlled amount of oxybutynin chloride …
Transdermal oxybutynin.
Baldwin CM, Keating GM. Baldwin CM, et al. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. Drugs. 2009. PMID: 19275276 Review.
*The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. ...*Transdermal oxybutynin is generally well tolerated in patients with overactive bladder. The majority of patients who discontinued tr …
*The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. ... …
[Management of hyperhidrosis].
Maillard H, Lecouflet M. Maillard H, et al. Ann Dermatol Venereol. 2015 Apr;142(4):252-61. doi: 10.1016/j.annder.2014.11.005. Epub 2015 Feb 16. Ann Dermatol Venereol. 2015. PMID: 25697587 Review. French.
We shall break down therapeutic approaches to hyperhidrosis into several steps: (a) determine the physiological causes of excess sweating; (b) establish the type of hyperhidrosis involved and screen for causes of secondary hyperhidrosis before diagnosing essential hyperhidrosis; …
We shall break down therapeutic approaches to hyperhidrosis into several steps: (a) determine the physiological causes of excess sweating; ( …
Oxybutynin-associated esotropia.
Wong EY, Harding A, Kowal L. Wong EY, et al. J AAPOS. 2007 Dec;11(6):624-5. doi: 10.1016/j.jaapos.2007.06.008. J AAPOS. 2007. PMID: 18086433
A 5-year-old girl with previously unrecognized hyperopia of approximately +3.00 D developed esotropia while being treated with oxybutynin for enuresis. The esotropia disappeared with cessation of oxybutynin and correction of her hyperopia. ...The esotropia was presu …
A 5-year-old girl with previously unrecognized hyperopia of approximately +3.00 D developed esotropia while being treated with oxybutynin …
Transdermal oxybutynin: a review.
Shaw GL, Patel HR. Shaw GL, et al. Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):435-9. doi: 10.1517/17425255.3.3.435. Expert Opin Drug Metab Toxicol. 2007. PMID: 17539749 Review.
Compliance is limited by these side effects. Transdermal administration of oxybutynin has been shown to be as effective as oral treatment while minimising the anticholinergic side effects. ...Here, the pharmacokinetics, pharmacodynamics, efficacy and safety of transdermal …
Compliance is limited by these side effects. Transdermal administration of oxybutynin has been shown to be as effective as oral treat …
S-oxybutynin.
[No authors listed] [No authors listed] Drugs R D. 2002;3(2):84-5. doi: 10.2165/00126839-200203020-00003. Drugs R D. 2002. PMID: 12001823 No abstract available.
[Oxybutynin-Kentera].
Duh D, Vandevijver A. Duh D, et al. J Pharm Belg. 2007;62(3):99-100. J Pharm Belg. 2007. PMID: 17955962 French. No abstract available.
Oxybutynin and the overactive bladder.
Andersson KE, Chapple CR. Andersson KE, et al. World J Urol. 2001 Nov;19(5):319-23. doi: 10.1007/pl00007103. World J Urol. 2001. PMID: 11760780 Review.
Oxybutynin is a tertiary amine, which undergoes an extensive first-pass metabolism. It has an active metabolite, N-desethyl oxybutynin, and the effect of oral oxybutynin is to a large extent exerted by this metabolite. ...Most probably, oral oxybutynin …
Oxybutynin is a tertiary amine, which undergoes an extensive first-pass metabolism. It has an active metabolite, N-desethyl oxybut …
A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.
Casselini CM, Parson HK, Frizzi KE, Marquez A, Smith DR, Guernsey L, Nemmani R, Tayarani A, Jolivalt CG, Weaver J, Fernyhough P, Vinik AI, Calcutt NA. Casselini CM, et al. Acta Neuropathol. 2024 Mar 25;147(1):60. doi: 10.1007/s00401-024-02710-4. Acta Neuropathol. 2024. PMID: 38526612 Free article. Clinical Trial.
Subjects received daily topical treatment with 3% oxybutynin gel or placebo for 6 months. The a priori designated primary endpoint, significant change in intra-epidermal nerve fibre density (IENFD) in skin biopsies taken before and after 20 weeks of treatments, was met by …
Subjects received daily topical treatment with 3% oxybutynin gel or placebo for 6 months. The a priori designated primary endpoint, s …
1,839 results